GRK6在恶性肿瘤中的研究进展  

Research Progress of GRK6 in Malignant Tumors

作　　者：梁心怡 杜润蕾[1] LIANG Xinyi;DU Runlei(College of Life Sciences,Wuhan University,Wuhan 430072,China)

机构地区：[1]武汉大学生命科学学院,湖北武汉430072

出　　处：《生物化工》2022年第6期156-161,共6页Biological Chemical Engineering

基　　金：国家自然科学基金青年基金项目(31501148)。

摘　　要：G蛋白偶联受体激酶6(GRK6)是一个能够磷酸化介导活化的G蛋白偶联受体(GPCR)发生同源脱敏的丝氨酸/苏氨酸激酶。由于GPCR是细胞接收和传递外界信号的关键受体,GRK6的失调会使部分GPCR信号传递紊乱,严重损害细胞的正常生理反应,导致疾病的发生。近年来,在多种恶性肿瘤中发现了GRK6的表达异常,且明显影响了肿瘤的生长、增殖和迁移能力。本文就GRK6在不同恶性肿瘤中的作用进行了概述,探讨了GRK6与肿瘤发生发展相关的分子机制,为未来进一步揭示GRK6与恶性肿瘤之间的关系提供参考。G protein-coupled receptor kinase 6 is a serine/threonine kinase that phosphorylates agonist-activated G protein-coupled receptors(GPCR)to mediate their homologous desensitization.Since GPCR are key receptors for cells to receive and transmit external signals,GRK6 dysfunction can disrupt part of GPCR signaling,thereby impairing normal physiological responses of cells and leading to the occurrence of certain diseases.In recent years,aberrant expression of GRK6 has been found in various malignant tumors,which affects tumor growth,proliferation and migration.This article summarizes the role of GRK6 in different malignant tumors,discusses the molecular mechanism related to GRK6 and tumor occurrence and development,and provides a reference for further revealing the relationship between GRK6 and malignant tumors in the future.

关 键 词：GRK6 恶性肿瘤 肿瘤迁移 

分 类 号：R730[医药卫生—肿瘤]